{"entity":{"type":"insider","cik":"0001414815","url":"/insider/0001414815","json_url":"/insider/0001414815.json","name":"MACKAY MARTIN","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":31,"n_filings":14,"first":"2014-05-15","last":"2022-01-12","span_basis":"filed_date"},"name_variants":[{"name":"MACKAY MARTIN","source":"filing","n_filings":14,"first_seen":"2014-05-15","last_seen":"2022-01-12"}],"transactions":[{"id":6644698,"accession":"0000899243-22-001801","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-001801","line_url":"/filing/0000899243-22-001801#line-4","is_derivative":false,"issuer_cik":"0001414815","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001414815","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4496.0,"shares_display":"4,496","price_per_share":10.65,"price_display":"10.65","price_state":"stated","total_value":47882.4,"total_display":"47,882.40","total_whole":"47,882","shares_owned_after":282609.0,"shares_owned_after_display":"282,609","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-12","scope":"insider"},{"id":6644696,"accession":"0000899243-22-001801","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-001801","line_url":"/filing/0000899243-22-001801#line-3","is_derivative":false,"issuer_cik":"0001414815","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001414815","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5504.0,"shares_display":"5,504","price_per_share":10.1,"price_display":"10.10","price_state":"stated","total_value":55590.4,"total_display":"55,590.40","total_whole":"55,590","shares_owned_after":278113.0,"shares_owned_after_display":"278,113","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-10","filed_date":"2022-01-12","scope":"insider"},{"id":4809522,"accession":"0000899866-17-000057","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899866-17-000057","line_url":"/filing/0000899866-17-000057#line-4","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":370.0,"shares_display":"370","price_per_share":132.5,"price_display":"132.50","price_state":"stated","total_value":49025.0,"total_display":"49,025.00","total_whole":"49,025","shares_owned_after":50688.0,"shares_owned_after_display":"50,688","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-01","filed_date":"2017-03-01","scope":"insider"},{"id":4809519,"accession":"0000899866-17-000057","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899866-17-000057","line_url":"/filing/0000899866-17-000057#line-3","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":625.0,"shares_display":"625","price_per_share":131.7,"price_display":"131.70","price_state":"stated","total_value":82312.5,"total_display":"82,312.50","total_whole":"82,313","shares_owned_after":38258.0,"shares_owned_after_display":"38,258","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-28","filed_date":"2017-03-01","scope":"insider"},{"id":4809511,"accession":"0000899866-17-000057","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899866-17-000057","line_url":"/filing/0000899866-17-000057#line-1","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":860.0,"shares_display":"860","price_per_share":131.2,"price_display":"131.20","price_state":"stated","total_value":112832.0,"total_display":"112,832.00","total_whole":"112,832","shares_owned_after":38883.0,"shares_owned_after_display":"38,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-27","filed_date":"2017-03-01","scope":"insider"},{"id":4605606,"accession":"0000899866-17-000037","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899866-17-000037","line_url":"/filing/0000899866-17-000037#line-1","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":217.0,"shares_display":"217","price_per_share":126.84,"price_display":"126.84","price_state":"stated","total_value":27524.28,"total_display":"27,524.28","total_whole":"27,524","shares_owned_after":39743.0,"shares_owned_after_display":"39,743","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-09","filed_date":"2017-02-10","scope":"insider"},{"id":5237833,"accession":"0000899866-17-000025","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899866-17-000025","line_url":"/filing/0000899866-17-000025","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2728.0,"shares_display":"2,728","price_per_share":125.69785190615836,"price_display":"125.70","price_state":"stated","total_value":342903.74,"total_display":"342,903.74","total_whole":"342,904","shares_owned_after":39978.0,"shares_owned_after_display":"39,978","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-06","filed_date":"2017-02-08","scope":"insider","n_lines":2},{"id":2544308,"accession":"0000899866-16-000316","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899866-16-000316","line_url":"/filing/0000899866-16-000316","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4097.0,"shares_display":"4,097","price_per_share":139.19544788869905,"price_display":"139.20","price_state":"stated","total_value":570283.75,"total_display":"570,283.75","total_whole":"570,284","shares_owned_after":42706.0,"shares_owned_after_display":"42,706","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-16","filed_date":"2016-05-18","scope":"insider","n_lines":2},{"id":2268719,"accession":"0000899866-16-000272","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899866-16-000272","line_url":"/filing/0000899866-16-000272#line-2","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":138.91,"price_display":"138.91","price_state":"stated","total_value":138910.0,"total_display":"138,910.00","total_whole":"138,910","shares_owned_after":46785.0,"shares_owned_after_display":"46,785","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-02-29","filed_date":"2016-03-01","scope":"insider"},{"id":2863298,"accession":"0000899866-16-000239","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899866-16-000239","line_url":"/filing/0000899866-16-000239","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1966.0,"shares_display":"1,966","price_per_share":138.08785350966428,"price_display":"138.09","price_state":"stated","total_value":271480.72,"total_display":"271,480.72","total_whole":"271,481","shares_owned_after":40785.0,"shares_owned_after_display":"40,785","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-02-08","filed_date":"2016-02-08","scope":"insider","n_lines":2},{"id":2863290,"accession":"0000899866-16-000239","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899866-16-000239","line_url":"/filing/0000899866-16-000239","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2005.0,"shares_display":"2,005","price_per_share":141.55761097256857,"price_display":"141.56","price_state":"stated","total_value":283823.01,"total_display":"283,823.01","total_whole":"283,823","shares_owned_after":42751.0,"shares_owned_after_display":"42,751","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-02-05","filed_date":"2016-02-08","scope":"insider","n_lines":5},{"id":2863276,"accession":"0000899866-16-000239","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899866-16-000239","line_url":"/filing/0000899866-16-000239#line-2","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":145.54,"price_display":"145.54","price_state":"stated","total_value":14554.0,"total_display":"14,554.00","total_whole":"14,554","shares_owned_after":44756.0,"shares_owned_after_display":"44,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-02-05","filed_date":"2016-02-08","scope":"insider"},{"id":8238133,"accession":"0000899866-15-000147","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899866-15-000147","line_url":"/filing/0000899866-15-000147","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":43500.0,"shares_display":"43,500","price_per_share":196.51536137931035,"price_display":"196.52","price_state":"stated","total_value":8548418.22,"total_display":"8,548,418.22","total_whole":"8,548,418","shares_owned_after":41775.0,"shares_owned_after_display":"41,775","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-08-03","filed_date":"2015-08-05","scope":"insider","n_lines":3},{"id":8482444,"accession":"0000899866-15-000125","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899866-15-000125","line_url":"/filing/0000899866-15-000125#line-1","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4056.0,"shares_display":"4,056","price_per_share":160.33,"price_display":"160.33","price_state":"stated","total_value":650298.48,"total_display":"650,298.48","total_whole":"650,298","shares_owned_after":32893.0,"shares_owned_after_display":"32,893","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-05-14","filed_date":"2015-05-22","scope":"insider"},{"id":8048843,"accession":"0000899866-15-000076","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899866-15-000076","line_url":"/filing/0000899866-15-000076#line-2","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":370.0,"shares_display":"370","price_per_share":180.34,"price_display":"180.34","price_state":"stated","total_value":66725.8,"total_display":"66,725.80","total_whole":"66,726","shares_owned_after":36949.0,"shares_owned_after_display":"36,949","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-02","filed_date":"2015-03-03","scope":"insider"},{"id":8653585,"accession":"0000899866-15-000052","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899866-15-000052","line_url":"/filing/0000899866-15-000052","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3897.0,"shares_display":"3,897","price_per_share":173.96866050808313,"price_display":"173.97","price_state":"stated","total_value":677955.87,"total_display":"677,955.87","total_whole":"677,956","shares_owned_after":34126.0,"shares_owned_after_display":"34,126","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-10","filed_date":"2015-02-12","scope":"insider","n_lines":2},{"id":6984077,"accession":"0000899866-14-000239","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899866-14-000239","line_url":"/filing/0000899866-14-000239#line-2","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9375.0,"shares_display":"9,375","price_per_share":191.52,"price_display":"191.52","price_state":"stated","total_value":1795500.0,"total_display":"1,795,500.00","total_whole":"1,795,500","shares_owned_after":24426.0,"shares_owned_after_display":"24,426","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-03","filed_date":"2014-11-04","scope":"insider"},{"id":7042636,"accession":"0000899866-14-000142","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899866-14-000142","line_url":"/filing/0000899866-14-000142","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":166.4226156,"price_display":"166.42","price_state":"stated","total_value":4160565.39,"total_display":"4,160,565.39","total_whole":"4,160,565","shares_owned_after":28419.0,"shares_owned_after_display":"28,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-06-12","filed_date":"2014-06-13","scope":"insider","n_lines":3},{"id":6359594,"accession":"0000899866-14-000129","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899866-14-000129","line_url":"/filing/0000899866-14-000129#line-1","is_derivative":false,"issuer_cik":"0000899866","issuer_name":"ALEXION PHARMACEUTICALS INC","issuer_ticker":"ALXN","issuer_name_source":null,"issuer_url":"/issuer/0000899866","owner_cik":"0001414815","owner_name":"MACKAY MARTIN","owner_display_name":"MACKAY MARTIN","owner_url":"/insider/0001414815","role":"Officer (EVP & Global Head of R&D)","role_mark":"O","role_mark_label":"Officer (EVP & Global Head of R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Global Head of R&D","security_title":"Common Stock, par value $.0001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3574.0,"shares_display":"3,574","price_per_share":160.85,"price_display":"160.85","price_state":"stated","total_value":574877.9,"total_display":"574,877.90","total_whole":"574,878","shares_owned_after":24426.0,"shares_owned_after_display":"24,426","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-05-14","filed_date":"2014-05-15","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":31,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":29,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":31},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001739410","name":"Rallybio Corp","url":"/issuer/0001739410","role":"Director, Officer (Chief Executive Officer)","n_filings":1,"first_seen":"2022-01-12","last_seen":"2022-01-12"},{"type":"issuer","type_label":"ISSUER","cik":"0000899866","name":"ALEXION PHARMACEUTICALS INC","url":"/issuer/0000899866","role":"Officer (EVP & Global Head of R&D)","n_filings":13,"first_seen":"2014-05-15","last_seen":"2017-03-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001414815","retrieved_at":"2026-08-24T05:04:08+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}